Medicine and Dentistry
Multiple Sclerosis
100%
Cohort Analysis
50%
Fumaric Acid Dimethyl Ester
50%
Disease Modifying Therapy
32%
Diseases
28%
Disability Pension
25%
Myasthenia gravis
25%
Encephalitis
25%
N Methyl-D-Aspartate Receptor
25%
Allergic Encephalitis
25%
Receptor Antibody
25%
Teriflunomide
25%
Expanded Disability Status Scale
12%
Adverse Event
10%
Modified Rankin Scale
10%
Autoimmune Disease
10%
Hazard Ratio
9%
Disease Course
7%
Lymphocytopenia
7%
Disease Activity
7%
Proportional Hazards Model
7%
Propionic Acid
5%
Cancer
5%
Immunosuppressive Treatment
5%
Neurotransmission
5%
Case Presentation
5%
Electrophysiology
5%
Autoantibodies
5%
Cell Surface
5%
Keyphrases
Multiple Sclerosis
50%
Dimethyl Fumarate
50%
Denmark
28%
N-methyl-D-aspartate Receptor Antibody
25%
Ocular Myasthenia Gravis
25%
Income Loss
25%
Autoimmune Synaptic Encephalitis
25%
High-efficacy Disease-modifying Therapy
25%
National Cohort Study
25%
Teriflunomide
25%
Hypertension Risk
25%
Hypertension
21%
Reasons for Discontinuation
14%
MS-group
10%
Fellow Patients
10%
Cladribine Tablets
9%
Population-based Study
7%
Adverse Events
7%
Discontinuation Rate
7%
Lymphopenia
7%
Adult Patients
7%
High Risk
7%
Ocrelizumab
5%
Isoxazole
5%
Surface Antibody
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
75%
Fumaric Acid Dimethyl Ester
50%
Cohort Study
26%
Cladribine
25%
Teriflunomide
25%
Adverse Event
14%
Lymphocytopenia
7%
Disease
6%
Tablet
6%
Disease Activity
5%
